AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 13 - Thomask Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomask Equels Today - Breaking & Trending Today
AIM ImmunoTech Inc moving to Phase 2 trials with Ampligen following promising data from cancer program
AIM ImmunoTech Inc (NYSE:AIM) CEO Thomas K. Equels joined Proactive's Stephen Gunnion to share an overview of the company's Pancreatic Cancer Program with...
Source: proactiveinvestors.com
AIM ImmunoTech reports additional patient data from
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and...
Source: globenewswire.com
NA Proactive news snapshot: LQwD Fintech Corp, Versus Systems Inc, Sassy Resources Corporation, Vuzix Corporation, Thunderbird Entertainment Group Inc UPDATE ...
LQwD Fintech Corp, a lightning network service provider, said it has appointed Aziz Pulatov as its chief technology officer. Pulatov has extensive...
Source: proactiveinvestors.com
AIM ImmunoTech Inc.: AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions - Including a Potential Hostile Takeover of the Company - and Prevent Group from Continued Violations of Federal Securities
Source: finanznachrichten.de